ECCO2R - Mechanical Power Study

Sponsor
University of Milan (Other)
Overall Status
Recruiting
CT.gov ID
NCT03939260
Collaborator
(none)
15
1
59.4
0.3

Study Details

Study Description

Brief Summary

Although mechanical ventilation remains the cornerstone of ARDS treatment, several experimental and clinical studies have undoubtedly demonstrated that it can contribute to high mortality through the developing of ventilator induced lung injury even in patients with plateau pressure <30 cmH2O. Since now there are no studies exploring the application of low flow extracorporeal CO2 removal and ultraprotective ventilation to reduce mechanical power, a composite index of VILI, independently from the value of plateau pressure or the severity of hypercapnia.

Condition or Disease Intervention/Treatment Phase
  • Other: Extracorporeal CO2 Removal

Study Design

Study Type:
Observational
Anticipated Enrollment :
15 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
The Effects of Low Flow Extracorporeal CO2 Removal on Mechanical Power in ARDS Patients
Actual Study Start Date :
Mar 20, 2019
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
Mar 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Mechanical Power reduction. [Changes from baseline to day 5.]

    Achievement of Mechanical Power reduction under 18 J/min while maintaining pH and PaCO2 to ± 20% of baseline values obtained at tidal volume of 6 mL/kg. Mechanical Power (MP) (J/min) = 0.098 * respiratory rate * tidal volume (inspiratory peak airway pressure - 1/2 * (airway pressure at end inspiratory pause - airway pressure at PEEP))

Secondary Outcome Measures

  1. Respiratory mechanics. [Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days]

    1. Respiratory system elastance (Ers) (cmH2O/L) = (airway pressure at end inspiratory pause - airway pressure at PEEP) / tidal volume

  2. Respiratory mechanics. [Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days]

    2. Lung elastance (El) (cmH2O/L) = (transpulmonary pressure at end inspiratory pause - transpulmonary pressure at PEEP / tidal volume

  3. Respiratory mechanics. [Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days]

    3. Chest wall elastance (Ecw) (cmH2O/L) = (esophageal pressure at end inspiratory pause - esophageal pressure at PEEP) / tidal volume

  4. Respiratory mechanics. [Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days]

    4. End inspiratory transpulmonary pressure (cmH2O)= airway pressure at end inspiratory pause - (esophageal pressure at end inspiratory pause - expiration at atmospheric pressure by a release manouvre).

  5. Gas exchange. [Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days]

    Assessment of changes in PaCO2 mmHg.

  6. Gas exchange. [Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days]

    Assessment of changes in PaO2 mmHg.

  7. Gas exchange. [Every six hours, every day until the fifth day or until the weaning from ECCO2R if lower than five days]

    Assessment of changes in PaO2/FiO2.

  8. Safety assessment and adverse device related events: frequency of serious adverse events [Every day, until the fifth day or until the weaning from ECCO2R if lower than five days]

    Safety assessment reporting frequency of serious adverse events in terms of device related mechanical events (Pump malfunction, membrane lung clotting, system leaks, tubing rupture, air in the circuit) and device related clinical events (heamolysis, significant bleeding, thromboembolic complications, neurologic complications, metabolic complications).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
ARDS patients undergoing mechanical ventilation with:
  • PaO2/FiO2 <150 with a level of positive end expiratory pressure (PEEP) of 10 cmH2O or higher with a FiO2 > 0.5

  • Plateau pressure of 28 cmH2O or higher with tidal volume of 6 ml/Kg of ideal body weight

  • Mechanical power of 18 J/min or higher.

Exclusion Criteria:
  • <18 years of age

  • Pregnancy

  • Obesity with BMI> 30

  • Platelets <30 G/l

  • Decompensated heart failure or acute coronary syndrome

  • Acute brain injury

  • Contraindication for systemic anticoagulation (for example, gastrointestinal bleeding, recent cerebrovascular accident, or chronic bleeding disorder, recent major surgery)

  • Patient moribund, decision to limit therapeutic interventions

  • Catheter access to femoral vein or jugular vein impossible

  • Pneumothorax.

Contacts and Locations

Locations

Site City State Country Postal Code
1 ASST-Santi Paolo e Carlo, San Paolo Hospital Milan Italy 20142

Sponsors and Collaborators

  • University of Milan

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Davide Chiumello, Professor, University of Milan
ClinicalTrials.gov Identifier:
NCT03939260
Other Study ID Numbers:
  • 13175/2019
First Posted:
May 6, 2019
Last Update Posted:
May 6, 2019
Last Verified:
May 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 6, 2019